Journal of Bioequivalence & Bioavailability

Bioequivalence Testing for Drugs with Complex Metabolism and Metabolic Variability

Nichole Shelby^* Department of Medical Sciences, University of Oxford, Oxford, United Kingdom
^*Correspondence: Nichole Shelby, Department of Medical Sciences, University of Oxford, Oxford, United Kingdom, Email:

Received: 25-Jul-2024, Manuscript No. JBB-24-26778; Editor assigned: 29-Jul-2024, Pre QC No. JBB-24-26778 (PQ); Reviewed: 12-Aug-2024, QC No. JBB-24-26778; Revised: 19-Aug-2024, Manuscript No. JBB-24-26778 (R); Published: 26-Aug-2024, DOI: 10.35248/0975-0851.24.16.594

Description

Bioequivalence studies are important in the approval process of generic drugs, ensuring that they match their brand-name counterparts in terms of efficacy, safety, and therapeutic effect. A significant aspect of these studies involves the comparison of drug metabolism, which can significantly influence the pharmacokinetic profiles of different formulations [1]. Variations in drug metabolism, driven by differences in enzymatic pathways, can lead to discrepancies in drug absorption, distribution, and elimination, ultimately affecting therapeutic outcomes [2].

Bioequivalence (BE) studies serve as a cornerstone in the development and approval of generic drugs, which are intended to be pharmacologically equivalent to their branded counterparts [3]. The primary objective of BE studies is to demonstrate that the generic product exhibits similar bioavailability defined as the rate and extent of drug absorption when administered under the same conditions as the innovator product. However, beyond the basic pharmacokinetic parameters of maximum concentration and Area Under the Curve (AUC), drug metabolism plays an important role in determining the therapeutic equivalence of these products [4].

Drug metabolism, the process by which a drug is chemically altered within the body, primarily occurs in the liver and involves various enzymes. Differences in metabolic pathways can lead to variations in drug exposure, efficacy, and safety profiles between generic and branded formulations [5]. These differences may arise due to factors such as excipient composition, drug formulation, and individual patient variability in enzyme activity [6].

Importance of drug metabolism in bioequivalence studies

Drug metabolism significantly influences the pharmacokinetics of a drug, impacting its Absorption, Distribution, Metabolism, and Excretion (ADME) processes. The extent and rate at which a drug is metabolized can affect its bioavailability, therapeutic efficacy, and potential for adverse effects. In the context of BE studies, it is essential to consider how differences in metabolic pathways may influence the pharmacokinetic profiles of generic and branded formulations [7,8].

For instance, a drug that is extensively metabolized by the liver may exhibit significant variability in bioavailability depending on the efficiency of metabolic enzymes. This variability can be further influenced by factors such as genetic polymorphisms in metabolic enzymes, drug-drug interactions, and differences in formulation excipients. Such factors can lead to variations in the extent of metabolism, resulting in differences in plasma drug concentrations and, consequently, therapeutic effects [9].

The significance of drug metabolism in BE studies is particularly pronounced for drugs with a Narrow Therapeutic Index (NTI), where small differences in drug exposure can lead to therapeutic failure or toxicity. For such drugs, even minor differences in metabolic pathways between generic and branded formulations can have clinically relevant implications, necessitating a thorough evaluation of metabolic equivalence [10].

Strategies for improving metabolic comparisons in BE Studies

The use of advanced analytical techniques, such as Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), can improve the sensitivity and specificity of metabolic measurements. These techniques allow for the precise quantification of drug metabolites and the identification of metabolic pathways, facilitating more accurate comparisons of metabolic profiles between generic and branded formulations. Additionally, the use of stable isotope-labeled compounds can enhance the accuracy of metabolic studies by providing internal standards for quantification.

When comparing drug metabolism in BE studies, it is important to carefully consider the impact of formulation excipients on metabolic pathways. Conducting invitro studies to evaluate the potential for excipient-induced enzyme inhibition or induction can provide valuable insights into how excipients may affect drug metabolism. Additionally, using excipients that have minimal impact on metabolic enzymes can help reduce variability and improve the consistency of metabolic comparisons. To account for potential DDIs in BE studies, researchers should conduct thorough drug interaction assessments during the design phase of the study. This may involve conducting in vitro studies to evaluate the potential for DDIs, as well as including a washout period between the administration of different drugs to minimize the risk of interactions. Additionally, stratifying study participants based on their concomitant medications can help control for the impact of DDIs on drug metabolism [11].

Physiologically-Based Pharmacokinetic (PBPK) modeling is an advanced computational approach that can simulate drug metabolism in different populations and under various physiological conditions. By incorporating data on enzyme activity, drug-drug interactions, and genetic variability, PBPK models can predict the impact of metabolic differences on drug pharmacokinetics. Using PBPK modeling in BE studies can help identify potential metabolic disparities between generic and branded formulations, guiding the design of more targeted and efficient studies.

References

1. Subhani S, Kim C, Muniz P, Rodriguez M, Van S, Suarez E, et al. Application of physiologically based absorption and pharmacokinetic modeling in the development process of oral modified release generic products. Eur J Pharm Biopharm. 2022;176:87-94.

   [Crossref] [Google Scholar] [PubMed]

2. Habet S. Narrow Therapeutic Index drugs: Clinical pharmacology perspective. J Pharm Pharmacol. 2021;73(10):1285-1291.

   [Crossref] [Google Scholar] [PubMed]

3. Gozzo L, Caraci F, Drago F. Bioequivalence, drugs with narrow therapeutic index and the phenomenon of biocreep: a critical analysis of the system for generic substitution. Healthcare (Basel). MDPI. 2022;10(8):1392.

   [Crossref] [Google Scholar] [PubMed]

4. Vinarov Z, Abdallah M, Agundez JA, Allegaert K, Basit AW, Braeckmans M, et al. Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review. Eur J Pharm Sci. 2021;162:105812.

   [Crossref] [Google Scholar] [PubMed]

5. Maurer AH. Gastrointestinal motility, part 2: small-bowel and colon transit. J Nucl Med Technol. 2016;44(1):12-8.

   [Crossref] [Google Scholar] [PubMed]

6. Hofsäss MA, Dressman J. Suitability of the z-factor for dissolution simulation of solid oral dosage forms: potential pitfalls and refinements. J Pharm Sci. 2020;109(9):2735-45.

   [Crossref] [Google Scholar] [PubMed]

7. Jinno JI, Kamada N, Miyake M, Yamada K, Mukai T, Odomi, et al. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release. 2006;111(1-2):56-64.

   [Crossref] [Google Scholar] [PubMed]

8. Mudie DM, Samiei N, Marshall DJ, Amidon GE, Bergström CA. Selection of in vivo predictive dissolution media using drug substance and physiological properties. AAPS J. 2020;22:1-3.

   [Crossref] [Google Scholar] [PubMed]

9. Bego M, Patel N, Cristofoletti R, Rostami-Hodjegan A. Proof of concept in assignment of within-subject variability during virtual bioequivalence studies: propagation of intra-subject variation in gastrointestinal physiology using physiologically based pharmacokinetic modeling. AAPS J. 2022;24(1):21.

   [Crossref] [Google Scholar] [PubMed]

10. An Z, Wang X, Li P, He J, Liu L. Exploring the metabolic characteristics and pharmacokinetic variation of paroxetine in healthy volunteers using a pharmacometabonomic approach. J Pharm Biomed Anal. 2021;204:114224.

    [Crossref] [Google Scholar] [PubMed]

11. Moon SJ, Kim Y, Jeon JY, Park SJ, Kwak YG, Kim MG. Pharmacokinetic properties and bioequivalence of gefitinib 250 mg in healthy Korean male subjects. Transl Clin Pharmacol. 2021;29(3):171.

    [Crossref] [Google Scholar] [PubMed]